Literature DB >> 29399584

Evaluation of two different enzyme-linked immunosorbent assay for severe fever with thrombocytopenia syndrome virus diagnosis.

Min-Ah Yu1,2, Hye Won Jeong3,4, Su-Jin Park1,2, Young-Il Kim1,2, Hyeok-Il Kwon1,2, Eun-Ha Kim1,2, Young-Jae Si1,2, Kwang Min Yu1,2, Norbert John Robles1,2, Hae Jung Han1,5, Young Ki Choi1,2.   

Abstract

To develop the large scale serological assay for severe fever with thrombocytopenia syndrome virus (SFTSV) infection, we evaluated two different enzyme-linked immunosorbent assay (ELISA) methods using nucleocapsid protein (NP) and Gn proteins of CB1 (genotype B) SFTSV strains. The NP-based ELISA tests showed more sensitive with broad cross-reactivity between two different genotype A and B strains compared with those of Gn-based ELISA tests. However, Gn-based ELISA showed more genotype specificity and specificity. These result suggested that NP-based ELISA test could be applicable for general sero-prevalence studies of SFTSV infections, while Gn-based ELISA could be applicable for a certain specific genotype sero-prevalence study.

Entities:  

Keywords:  Enzyme-linked immunosorbent assay; Gn protein; NP protein; Severe fever with thrombocytopenia syndrome virus

Year:  2018        PMID: 29399584      PMCID: PMC5795049          DOI: 10.7774/cevr.2018.7.1.82

Source DB:  PubMed          Journal:  Clin Exp Vaccine Res        ISSN: 2287-3651


Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerged tick-mediated infectious disease in humans which belongs to the family Bunyaviridae and has three single-stranded RNA segments consisting of S, M, and L segments [12]. Since SFTS infectious disease was first reported in China, 2009 [3], severe fever with thrombocytopenia syndrome virus (SFTSV) has been also reported in South Korea (2013) and Japan (2013) [45]. Although the name of SFTS is derived from the clinical symptoms of the disease, severe fever and thrombocytopenia, the clinical manifestation of SFTS is nonspecific and difficult to distinguish from those of human granulocytic anaplasmosis, leptospirosis, Orientia tsutsugamushi infection, and hemorrhagic fever with renal syndrome [6]. The SFTSV was also isolated from the domesticated animal farms with high seroprevalence where SFTS human patients were previously reported with high genetic homology [78]. Further, recent studies showed high heritage diversity of SFTSV strains in East Asia (genotypes A to F) [9]. Therefore, the sensitive and specific serological diagnosis methods are needed to understand the sero-prevalence of multiple genotypes of SFTSV strains. To detect anti-SFTSV antibodies in sera from infected hosts, immunofluorescence assay (IFA) is routinely used as a reference test for high sensitivity, but it has nonspecific interactions with various viral antigens that cause poor specificity [10]. Further, this IFA method has several disadvantages, such as the need to handle the live virus, which requires special facilities with high-level biosafety equipment and laborious to apply for large numbers of serum samples [11]. Due to these limitations, in-house indirect enzyme-linked immunosorbent assays (ELISA) and double-antigen sandwich ELISA have been developed to detect immunoglobulins with the nucleocapsid protein (NP) of SFTSV [121314]. However, limited ELISA methods are utilized the Gn protein which is the main surface glycoprotein to produce the neutralizing antibody against SFTSV infection [15]. In this study, we developed the antibody capture ELISA method with Escherichia coli expressed NP and Gn proteins of CB1 (genotype B) Korean strain and compared their sensitivity and specificity with SFTSV confirmed human and experimentally infected ferret sera including each of negative sera. To evaluate the sensitivity and specificity of our ELISA, we adapted the IFA test as a reference analysis. To this end, two previously reported CB1 (genotype B) and CB2 (genotype A) SFTSV strains [16] were used for antigen preparedness and each genotype specific antibody generations. Briefly, each genotype specific SFTSV positive sera were generated from the immunization of inactivated CB1 (genotype B) and CB2 (genotype A) SFTSV strains in SFTSV negative ferrets (n=3). To eliminate the any possible growth of SFTSV in immunized ferrets, SFTSV specific real time reverse transcriptase-polymerase chain reaction using the white cells of the ferrets every 3 dpi. No virus was detected from all the time points (data not shown). After the second vaccination, whole serums were collected and combined from each ferret and used as a CB1- or CB2-positive reference antibody sera. All animal experiments were approved by the Medical Research Institute, a member of Laboratory Animal Research Center of Chungbuk National University (LARC) (approval number: CBNUA-986-16-01) and were conducted in strict accordance and adherence to relevant policies regarding animal handling as mandated under the Guidelines for Animal Use and Care of the Korea Center for Disease Control and Prevention (KCDC). The handling of viruses was performed in an enhanced biosafety level 3 (BSL3) containment laboratory as approved by the KCDC (KCDC-14-3-07). To use the ELISA coating antigens, E. coli expressed recombinant NP and Gn proteins of CB1 strain were purified as described in elsewhere [1718]. Then, 100 ng per well of purified each protein was coated onto Polysorp ELISA plates (Nunc, Rochester, NY, USA) for 16 hours at 4℃. After the blocking to prevent non-specific binding, 10-fold diluted serum were incubated on coated plates for 5 hours and horseradish peroxidase peroxidase (HRP)–conjugated anti body (1:1,000) were incubated for 2 hours. Following the washing with phosphate buffered saline with Tween-20 (PBST), ortho-phenylenediamine peroxidase substrate (Sigma, St. Louis, MO, USA) was added as the HRP substrate. The color development was terminated with 1N H2SO4. The optical density (OD) was measured spectrophotometrically at 490 nm. For comparison study, the IFA was performed as a slightly modified previously described [19]. Briefly, Vero E6 cells in 6-well plates were infected with 1 mL of 1×103 TCID50/mL of CB1 and CB2 SFTSV strains for 2 hours at 37℃ and incubated with 3 days. The infected cells were fixed with 80% acetone solution. The serially diluted field serum samples were incubated with fixed cells for 3 hours at 37℃, and the fluorescence was detected using fluorescein isothiocyanate–labeled secondary antibodies. The fluorescence was observed using an Olympus IX 71 (Olympus, Tokyo, Japan) microscope and DP controller software to capture images. To assess significant differences in ELISA between positive and neagative samples were compared. Asterisks indicate the statistical significance between negative and other sampels determined by t test. All statistical analyses were performed with using GraphPad Prism version 5.00 for Windows (GraphPad Software, La Jolla, CA, USA). To evaluate our NP- and Gn protein–based ELISAs, we used our laboratory generated CB1 and CB2 genotype specific SFTSV-positive ferret sera which were confirmed antibody titers by IFA test. NP-based ELISA test against CB1 strain anti-sera showed 1.01–1.18 OD value and increased up to 1.64–1.92 OD value by boosting immunization (Fig. 1A). Further, Gn-based ELISA test also showed relative high OD value 1.04 to 1.49 and increased to 1.07–1.98 by boosting immunization against homologous CB1 strain. In heterologous genotype assay with CB2 (genotype A) anti-sera, NP-based ELISA result showed almost similar OD values as 1.00-1.14 OD value and increased up to 1.54–1.82 OD value by boosting immunization. However, Gn-base ELISA showed relatively low OD values as 0.80–1.08 compared with those of homologous genotype assay even by boosting immunization. However, mock (PBS) immunized ferret sera showed low OD values as 0.15 to 0.27 in both assays. The IFA results showed that CB2 ferret anti-sera could detect the both CB1 (genotype B) and CB2 (genotype A) viruses in Vero E6 cell although the higher intensity of IFA was observed in homologous virus and the detection limit was 1:400. (Fig. 1B). To confirm the antigenic difference between SFTSV genotype A and B strains, we adapted Western blot assay with purified CB1 and CB2 strains by ultracentrifugation (25,000 rpm, 3 hours, XE-90, Beckman Coulter, Brea, CA, USA). Western blot assay showed that purified CB1 and CB2 viruses showed different pattern of positive bands against Gn/Gc proteins although the NP specific bands were detected in both antibodies (Fig. 1C). The CB1 immunized sera could detect the specific Gn proteins of CB1 virus, but it only detects unclear Gn bands of CB2 strains (Fig. 1C, left panel). Further, reversed pattern was detected in CB2 anti-sera test (Fig. 1C, right panel). These result suggested that there are antigenic differences between genotype A and B SFTSV strains.
Fig. 1

Detection of severe fever with thrombocytopenia syndrome virus (SFTSV) protein by ferret serum. (A) An r-NP and r-Gn based enzyme-linked immunosorbent assay was performed using the positive ferret serum CB1 and CB2. Positive samples demonstrated an optical density (OD) greater than 0.7. (B) After the infection of SFTSV, IFA was performed with CB1 and CB2 positive ferret serum. Two positive serums were detected over the 1:800. (C) Western blotting were performed with CB1 and CB2 proteins. First antibodies were used with CB1 positive serum and CB2 positive serum. M; protein marker; NP, nucleocapsid protein.

In addition, to evaluate the Gn-and NP-based ELISAs with human sera, seven confirmed SFTSV and 20 negative human sera by IFA were evaluated for both ELISA assay. These SFTSV suspected sera were collected from Chungbuk National University hospital to identify infection of SFTSV with patients' permissions. The diagnosis and related research of SFTSV suspected patients' specimens were authorized by Ethics Committee of the Faculty of Medicine at Chungbuk National University (approval No. IRB 2017-05-002-001). NP-based ELSIA results showed 1.08 to 1.29 OD in seven SFTSV positive sera (Fig. 2A). However, Gn-based ELISA showed relatively broad ranges of OD values from 0.74 to 1.40 against SFTSV positive sera although all negative sera showed low basal levels of OD values as 0.20 to 0.42 (Fig. 2B). Interestingly, the P1 and P2 sera showed higher OD values in Gn-based ELISA compared with NP-based ELISA tests, while three positive samples (P5, P6, and P7) showed significantly lower OD values in Gn-based ELISA than those of NP-based ELISA (1.15–1.18 vs. 0.91–0.95) (Fig. 2A). These results suggested that multiple genotypes of SFTSV strains are co-circulating in South Korea and they might be serologically differentiated by surface glycoproteins such as Gn protein. Further, NP-based ELISA showed broader cross reactivity between different genotypes of SFTSVs, while Gn-based ELISA could support to each Genotype specific antibody responses.
Fig. 2

Detection of severe fever with thrombocytopenia syndrome virus protein by ferret serum. (A) An r-NP and r-Gn based enzyme-linked immunosorbent assay (ELISA) was performed using the positive human serum. (B) An r-NP and r-Gn based ELISA was performed using the negative human serum. OD, optical density; NP, nucleocapsid protein.

In this study, we established NP- and Gn-based ELISA methods with E. coli expressed genotype B (CB1) which is most prevalence strain in Korea [16]. Both NP- and Gn-based ELISA methods showed relatively well agreement against homology SFTSV CB1 strain. Further Gn-based ELISA showed more rapid and high OD values against the homologous CB1 immunized ferret sera, but delayed (needed boosting) and relatively low OD value against the heterologous CB2 immunized ferret sera. Comparative results showed that the NP-based ELISA method was more advantageous for evaluating general sero-prevalence because of its higher cross-reactivity between SFTSV genotypes. However, Gn-based ELISA method could be applicable to establish genotype specific diagnosis methods. Taken together, we believed that the NP- and Gn-based ELISA methods established in this study can be useful for the measurement of infection rates in animals as well as humans.
  18 in total

1.  Development and evaluation of an in vitro virus isolation procedure as a replacement for the mouse inoculation test in rabies diagnosis.

Authors:  R J Rudd; C V Trimarchi
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

Review 2.  The emergence and cross species transmission of newly discovered tick-borne Bunyavirus in China.

Authors:  Yong-Zhen Zhang; Jianguo Xu
Journal:  Curr Opin Virol       Date:  2016-03-04       Impact factor: 7.090

3.  Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus.

Authors:  Bianli Xu; Licheng Liu; Xueyong Huang; Hong Ma; Yuan Zhang; Yanhua Du; Pengzhi Wang; Xiaoyan Tang; Haifeng Wang; Kai Kang; Shiqiang Zhang; Guohua Zhao; Weili Wu; Yinhui Yang; Haomin Chen; Feng Mu; Weijun Chen
Journal:  PLoS Pathog       Date:  2011-11-17       Impact factor: 6.823

4.  Severe fever with thrombocytopenia syndrome virus, Shandong Province, China.

Authors:  Li Zhao; Shenyong Zhai; Hongling Wen; Feng Cui; Yuanyuan Chi; Ling Wang; Fuzhong Xue; Qian Wang; Zhiyu Wang; Shoufeng Zhang; Yanyan Song; Jun Du; Xue-jie Yu
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

Review 5.  Systematic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics.

Authors:  Shelan Liu; Chengliang Chai; Chengmin Wang; Said Amer; Huakun Lv; Hongxuan He; Jimin Sun; Junfen Lin
Journal:  Rev Med Virol       Date:  2013-12-06       Impact factor: 6.989

6.  Molecular genomic characterization of tick- and human-derived severe fever with thrombocytopenia syndrome virus isolates from South Korea.

Authors:  Seok-Min Yun; Su-Jin Park; Sun-Whan Park; WooYoung Choi; Hye Won Jeong; Young-Ki Choi; Won-Ja Lee
Journal:  PLoS Negl Trop Dis       Date:  2017-09-22

7.  Severe fever with thrombocytopenia syndrome virus among domesticated animals, China.

Authors:  Guoyu Niu; Jiandong Li; Mifang Liang; Xiaolin Jiang; Mei Jiang; Haiying Yin; Zhidian Wang; Chuan Li; Quanfu Zhang; Cong Jin; Xianjun Wang; Shujun Ding; Zheng Xing; Shiwen Wang; Zhenqiang Bi; Dexin Li
Journal:  Emerg Infect Dis       Date:  2013-05       Impact factor: 6.883

8.  Application of recombinant severe fever with thrombocytopenia syndrome virus nucleocapsid protein for the detection of SFTSV-specific human IgG and IgM antibodies by indirect ELISA.

Authors:  Fuxun Yu; Yanhua Du; Xueyong Huang; Hong Ma; Bianli Xu; Ferdinard Adungo; Daisuke Hayasaka; Corazon C Buerano; Kouichi Morita
Journal:  Virol J       Date:  2015-08-04       Impact factor: 4.099

9.  Phylogeographic analysis of severe fever with thrombocytopenia syndrome virus from Zhoushan Islands, China: implication for transmission across the ocean.

Authors:  Yongfeng Fu; Shibo Li; Zhao Zhang; Suqin Man; Xueping Li; Wenhong Zhang; Chiyu Zhang; Xunjia Cheng
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

10.  The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan.

Authors:  Toru Takahashi; Ken Maeda; Tadaki Suzuki; Aki Ishido; Toru Shigeoka; Takayuki Tominaga; Toshiaki Kamei; Masahiro Honda; Daisuke Ninomiya; Takenori Sakai; Takanori Senba; Shozo Kaneyuki; Shota Sakaguchi; Akira Satoh; Takanori Hosokawa; Yojiro Kawabe; Shintaro Kurihara; Koichi Izumikawa; Shigeru Kohno; Taichi Azuma; Koichiro Suemori; Masaki Yasukawa; Tetsuya Mizutani; Tsutomu Omatsu; Yukie Katayama; Masaharu Miyahara; Masahito Ijuin; Kazuko Doi; Masaru Okuda; Kazunori Umeki; Tomoya Saito; Kazuko Fukushima; Kensuke Nakajima; Tomoki Yoshikawa; Hideki Tani; Shuetsu Fukushi; Aiko Fukuma; Momoko Ogata; Masayuki Shimojima; Noriko Nakajima; Noriyo Nagata; Harutaka Katano; Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Takuya Yamagishi; Kazunori Oishi; Ichiro Kurane; Shigeru Morikawa; Masayuki Saijo
Journal:  J Infect Dis       Date:  2013-11-14       Impact factor: 5.226

View more
  2 in total

1.  Seroprevalence of Severe Fever with Thrombocytopenia Syndrome Phlebovirus in Domesticated Deer in South Korea.

Authors:  Min-Ah Yu; Kwang-Min Yu; Su-Jin Park; Young-Il Kim; Norbert John Robles; Young-Jae Si; Eun-Ha Kim; Hyeok-Il Kwon; Hye Won Jeong; Min-Suk Song; Seok-Yong Kim; Young Ki Choi
Journal:  Virol Sin       Date:  2019-06-25       Impact factor: 4.327

2.  Cross-genotype protection of live-attenuated vaccine candidate for severe fever with thrombocytopenia syndrome virus in a ferret model.

Authors:  Kwang-Min Yu; Su-Jin Park; Min-Ah Yu; Young-Il Kim; Younho Choi; Jae U Jung; Benjamin Brennan; Young Ki Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-09       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.